• Something wrong with this record ?

Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells

V. Foltankova, S. Legartova, S. Kozubek, E. Bartova

. 2012 ; 59 (4) : 450-462.

Language English Country Slovakia

Document type Journal Article, Research Support, Non-U.S. Gov't

Understanding the epigenetics of tumor cells is of clinical significance for the treatment of cancer, and thus, chemists have focused their efforts on the synthesis of new generation of inhibitors of histone deacetylases (HDACs) or methylation-specific enzymes as novel important anti-cancer drugs. Here, we tested whether the histone signature and DNA methylation in multiple myeloma (MM) and leukemia cells is tumor-specific as compared with that in non-malignant lymphoblastoid cells. We observed a distinct histone signature in c-myc, Mcl-1, and ribosomal gene loci in MOLP8 MM and K562 leukemia cells, when compared with lymphoblastoid cells. Histone and DNA methylation patterns in MOLP8 cells were partially modified by the clinically promising HDAC inhibitor, vorinostat. In comparison with lymphoblastoid WIL2NS cells, MOLP8 cells and K562 cells were characterized by an absence of the gene silencing marker H3K9me2 in the c-myc and ribosomal genes. However, high levels of H3K27me3 were detected in the promoters and coding regions of selected genomic regions in these cells. Treatment by vorinostat increased the level of DNA methylation at the c-myc promoter, and this alteration was accompanied by a decrease in c-MYC protein. In MOLP8 cells, vorinostat significantly increased the H3K9 acetylation in the Mcl-1 coding regions and promoter. Both MOLP8 and K562 leukemia cells were characterized by decreased levels of H3K9me2 in the Mcl-1 gene as compared with lymphoblastoid WIL2NS cells. Lower levels of H3K9me1 in the Mcl-1 promoter, however, were specific for MM cells as compared with the other cell types studied. In other MM and leukemia cell lines, COLO677, OPM2, and U937, the ribosomal genes were less prone to epigenetic heterogeneity as compared to the c-myc and Mcl-1 proto-oncogenes. Taken together, these data describe both tumor-specific and loci-specific histone signature and DNA methylation profiles.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12034587
003      
CZ-PrNML
005      
20160904075131.0
007      
ta
008      
121023s2012 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2012_058 $2 doi
035    __
$a (PubMed)22489701
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Foltánková, Veronika $7 xx0121909 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, CZ-612 65, Brno, Czech Republic
245    10
$a Tumor-specific histone signature and DNA methylation in multiple myeloma and leukemia cells / $c V. Foltankova, S. Legartova, S. Kozubek, E. Bartova
520    9_
$a Understanding the epigenetics of tumor cells is of clinical significance for the treatment of cancer, and thus, chemists have focused their efforts on the synthesis of new generation of inhibitors of histone deacetylases (HDACs) or methylation-specific enzymes as novel important anti-cancer drugs. Here, we tested whether the histone signature and DNA methylation in multiple myeloma (MM) and leukemia cells is tumor-specific as compared with that in non-malignant lymphoblastoid cells. We observed a distinct histone signature in c-myc, Mcl-1, and ribosomal gene loci in MOLP8 MM and K562 leukemia cells, when compared with lymphoblastoid cells. Histone and DNA methylation patterns in MOLP8 cells were partially modified by the clinically promising HDAC inhibitor, vorinostat. In comparison with lymphoblastoid WIL2NS cells, MOLP8 cells and K562 cells were characterized by an absence of the gene silencing marker H3K9me2 in the c-myc and ribosomal genes. However, high levels of H3K27me3 were detected in the promoters and coding regions of selected genomic regions in these cells. Treatment by vorinostat increased the level of DNA methylation at the c-myc promoter, and this alteration was accompanied by a decrease in c-MYC protein. In MOLP8 cells, vorinostat significantly increased the H3K9 acetylation in the Mcl-1 coding regions and promoter. Both MOLP8 and K562 leukemia cells were characterized by decreased levels of H3K9me2 in the Mcl-1 gene as compared with lymphoblastoid WIL2NS cells. Lower levels of H3K9me1 in the Mcl-1 promoter, however, were specific for MM cells as compared with the other cell types studied. In other MM and leukemia cell lines, COLO677, OPM2, and U937, the ribosomal genes were less prone to epigenetic heterogeneity as compared to the c-myc and Mcl-1 proto-oncogenes. Taken together, these data describe both tumor-specific and loci-specific histone signature and DNA methylation profiles.
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a chromatinová imunoprecipitace $7 D047369
650    _2
$a metylace DNA $7 D019175
650    _2
$a epigeneze genetická $x genetika $7 D044127
650    _2
$a fluorescenční protilátková technika $7 D005455
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a histony $x genetika $7 D006657
650    _2
$a lidé $7 D006801
650    _2
$a leukemie $x genetika $7 D007938
650    _2
$a mnohočetný myelom $x genetika $7 D009101
650    _2
$a promotorové oblasti (genetika) $x genetika $7 D011401
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Legartová, Soňa $7 _AN046546 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
700    1_
$a Kozubek, Stanislav, $d 1953- $7 ola2003204933 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, CZ-612 65, Brno, Czech Republic
700    1_
$a Bártová, Eva $7 xx0028314 $u Institute of Biophysics, Academy of Sciences of the Czech Republic, Královopolská 135, CZ-612 65, Brno, Czech Republic
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 59, č. 4 (2012), s. 450-462
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22489701 $y Pubmed
910    __
$a ABA008 $b A 1194 $c 659 $y p $z 0
990    __
$a 20121023 $b ABA008
991    __
$a 20160904075439 $b ABA008
999    __
$a ok $b bmc $g 956597 $s 792084
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 59 $c 4 $d 450-462 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$b NLK122 $a Pubmed-20121023

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...